Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Novo Nordisk A/S | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
In this era of pharmaceutical and technological advancements, gaining insights into prevalent insulin administration practices under real-life conditions becomes pivotal for healthcare professionals. The investigators aim to explore insulin injection habits through an online survey among a broad, unselected group of participants with type 1 and type 2 diabetes undergoing daily prandial and/or basal insulin treatment. Eligible participants will access and complete the survey at their convenience after providing online informed consent within the study period
HYPOTHESIS The study hypothesis posits that there is significant variability in the practices of insulin administration among patients with diabetes using daily insulin injections. This diversity in administration practices may have a notable impact on the overall efficacy of treatment regimens and the successful management of the disease, thereby emphasizing the need for a comprehensive understanding of these practices to enhance patient outcomes and optimize diabetes care.
OBJECTIVES The main objective of the study is to comprehensively assess and characterize the diverse insulin administration practices among individuals with diabetes using injections, focusing on both prandial and basal insulin. By employing an online survey methodology and targeting a broad demographic through a diabetes information platform Canal Diabetes, the investigators aim to gain valuable insights into the variability, challenges, and overall patterns of insulin administration. The findings will contribute to a better understanding of real-world practices, facilitating improvements in patient guidance and optimizing diabetes care strategies.
STUDY DESIGN The study follows a cross-sectional observational design, allowing the investigators to capture a snapshot of the current insulin administration practices via an online questionnaire among the diverse population of diabetes patients using multiple insulin injections.
STUDY PROCEDURE AND SCHEDULE The study, focusing on insulin administration practices among participants with diabetes using multiple insulin injections, will employ a two-month online survey accessible on the designated online platform Canal Diabetes. Recruitment efforts through the diabetes information platform Canal Diabetes will inform eligible participants about the study's voluntary nature, emphasizing response confidentiality. Participants meeting the criteria, will access and complete the online informed consent and survey at their convenience within the designated two-month period. Post-survey, collected data will be securely stored and anonymized for subsequent analysis.
STUDY DURATION The anticipated duration of this study will be 4 months, with subject recruitment set to begin in July 2024 and aiming for the completion of statistical analysis by the 31st of October 2024.
GOOD CLINICAL PRACTICE The procedures set out in this study protocol, pertaining to the conduct, evaluation, and documentation of this study, are designed to ensure that the sponsor and investigator (in this case the same person) comply with the principle of the good clinical practice guidelines and the Declaration of Helsinki in the conduct, evaluation and documentation of this study. The study will also be carried out in keeping with local legal requirements.
SUBJECTS INFORMATION AND INFORMED CONSENT Prior to taking the online questionnaire, participants will be required to provide explicit consent to participate in the study. An online informed consent document, encompassing details about the study and the consent form, will be prepared and supplied to participants. This document will be presented in a language accessible to participants, and clear contact information will be provided for any questions that may arise.
ENSURING DATA CONFIDENTIALITY The study database will not contain any information that could allow the individual identification of the study participants. The data obtained will be used exclusively for the purposes described in this research project. The information will be treated as confidential and will be stored and processed in accordance with the provisions of EU Regulation 2016/679 of the European Parliament and the Council of 27 April 2016 on the protection of personal data and the free movement of such data, as well as Organic Law 3/2018 of December.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Number of total insulin injections | Number of total insulin injections per day | through study completion, an average of 16 weeks |
| Number of prandial insulin injections | Number of prandial insulin injections per day | through study completion, an average of 16 weeks |
| Number of basal insulin injections | Number of basal insulin injections per day | through study completion, an average of 16 weeks |
| Timing of prandial insulin injection | Timing of prandial insulin injection: before meals, during meals, after meals, or at some point during the day | through study completion, an average of 16 weeks |
| Time interval before prandial insulin injection | If insulin administration occurs before starting the meal: time interval (minutes) | through study completion, an average of 16 weeks |
| Time interval after prandial insulin injection | If insulin administration occurs after the meal: time interval (minutes) | through study completion, an average of 16 weeks |
| Insulin overdosing | Insulin overdosing when correcting abnormal glucose values (Y/N) | through study completion, an average of 16 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Individuals aged 18 or above, diagnosed with either Type 1 or Type 2 diabetes, who actively incorporate insulin injections-both prandial and basal-into their treatment plan, with a minimum requirement of at least one injection of prandial insulin and/or basal insulin.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ana Palanca | Contact | 961973517 | ana.palanca@gmail.com | |
| F. Javier Ampudia-Blasco | Contact | 961973500 | ampudia_fra@gva.es |
| Name | Affiliation | Role |
|---|---|---|
| F. Javier Ampudia-Blasco | HCUV-INCLIVA | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| INCLIVA | Valencia | 46010 | Spain |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Aug 31, 2025 | |
| Reset | Sep 18, 2025 | |
| Release | Sep 23, 2025 | |
| Reset | Oct 10, 2025 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Aug 31, 2025 | Sep 18, 2025 | |||
| Sep 23, 2025 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Insulin underdosing |
Insulin overdosing when correcting abnormal glucose values (Y/N) |
| through study completion, an average of 16 weeks |
| Insulin administration site | Insulin administration site: abdomen, thigh, arm | through study completion, an average of 16 weeks |
| Site rotation | Injection site rotation: (Yes/No) | through study completion, an average of 16 weeks |
| Change of the insulin needle | Frequency in the change of the insulin needle | through study completion, an average of 16 weeks |
| Use of smart pens | Use of smart pens (Y/N) | through study completion, an average of 16 weeks |
| Type of prandial insulin | Type of prandial insulin used | through study completion, an average of 16 weeks |
| Daily dose of prandial insulin | Daily dose of prandial insulin (IU/kg) | through study completion, an average of 16 weeks |
| Type of basal insulin | Type of basal insulin used | through study completion, an average of 16 weeks |
| Daily dose of basal insulin | Daily dose of basal insulin (IU/kg) | through study completion, an average of 16 weeks |
| Last HbA1c | Last HbA1c value | through study completion, an average of 16 weeks |
| Date of last HbA1c | Date of last HbA1c value | through study completion, an average of 16 weeks |
| Diabetic ketoacidosis | Diabetic ketoacidosis (DKA) in the last year (Y/N) | through study completion, an average of 16 weeks |
| Hypoglycemic episodes | Severe hypoglycemic episodes in the last year (Y/N) | through study completion, an average of 16 weeks |
| Hyperglycemic episodes | Hyperglycemic episodes with medical support in the last year (Y/N) | through study completion, an average of 16 weeks |
| Age of diabetes onset | Age of diabetes onset (years/months) | through study completion, an average of 16 weeks |
| Self-monitoring of capillary glucose | Self-monitoring of capillary blood glucose (SMBG) (Y/N) | through study completion, an average of 16 weeks |
| Glucose monitoring in real-time or intermittently scanned | Continuous glucose monitoring (CGM) in real-time or intermittently scanned (Y/N) | through study completion, an average of 16 weeks |
| Lack of daily glucose monitoring | Lack of daily glucose monitoring (Y/N) | through study completion, an average of 16 weeks |
| Lack of correction based on glucose values | Lack of correction based on glucose values (Y/N) | through study completion, an average of 16 weeks |
| Time in Range (%TIR) | If CGM user, CGM parameters from the last 28 days: Time in Range (%TIR) | through study completion, an average of 16 weeks |
| Time Below Range (%TbR) | If CGM user, CGM parameters from the last 28 days: Time Below Range (%TbR) | through study completion, an average of 16 weeks |
| Time Above Range (%TaR) | If CGM user, CGM parameters from the last 28 days: Time Above Range (%TaR) | through study completion, an average of 16 weeks |
| Mean glucose (mg/dL) | If CGM user, CGM parameters from the last 28 days: mean glucose (mg/dL) | through study completion, an average of 16 weeks |
| Coefficient of variation of continuous glucose sensor values (CV) | If CGM user, CGM parameters from the last 28 days: coefficient of variation of continuous glucose sensor values (CV) | through study completion, an average of 16 weeks |
| Oct 10, 2025 |